Why Patients with Psoriasis Should Avoid Systemic Prednisone
Systemic corticosteroids like prednisone are strongly discouraged in psoriasis because they can trigger severe disease flares—including potentially life-threatening pustular or erythrodermic psoriasis—upon dose reduction or withdrawal, despite being widely misprescribed in clinical practice.
The Core Problem: Rebound Flares
The primary concern with systemic corticosteroids in psoriasis is the risk of disease deterioration after tapering or discontinuation 1. While the exact mechanism isn't fully understood, the withdrawal of systemic immune suppression can precipitate:
- Pustular psoriasis transformation: The disease can shift from stable plaque psoriasis to generalized pustular psoriasis, a medical emergency 2, 3
- Erythrodermic flares: Widespread inflammation affecting >90% of body surface area 3
- Severe worsening of plaque psoriasis: Even without morphologic change, disease severity can dramatically increase 3, 4
Evidence on Flare Rates
Recent data provides nuanced perspective on actual risk:
- A 2021 Danish survey found that 50% of dermatologists and 29% of rheumatologists had observed at least one psoriasis flare following oral corticosteroid treatment 3
- However, a 2021 retrospective cohort study of 516 patients found a relatively low overall flare rate of 1.42% (95% CI, 0.72%-2.44%) during or within 3 months of first corticosteroid exposure, with severe flares (pustular or erythrodermic) occurring in only 0.07% 4
- The discrepancy between traditional teaching and observed rates suggests the risk may be lower than historically believed, but when flares occur, they can be severe and potentially life-threatening 4
The Misprescription Problem
Despite clear guideline recommendations against their use, systemic corticosteroids remain among the most commonly prescribed systemic treatments for psoriasis 5, 6:
- In U.S. data from 1989-2010, corticosteroids were the second most commonly prescribed systemic medication for psoriasis, with 650,000 prescriptions at psoriasis visits 5
- German healthcare data showed systemic corticosteroids were prescribed more frequently than guideline-recommended agents like methotrexate or fumaric acid esters 6
- This widespread use occurs primarily by general practitioners and internists, with dermatologists also contributing 6
Additional Safety Concerns from FDA Labeling
Beyond psoriasis-specific risks, prednisone carries general warnings relevant to all patients 7:
- Immunosuppression: Increased risk of serious infections (bacterial, viral, fungal, parasitic) that can be fatal 7
- HPA axis suppression: Risk of adrenal insufficiency upon withdrawal 7
- Cardiovascular effects: Fluid retention, hypertension, increased risk of left ventricular rupture post-MI 7
- Metabolic effects: Hyperglycemia, osteoporosis, weight gain 7
Clinical Bottom Line
Avoid systemic corticosteroids for psoriasis treatment 1. The 2020 AAD-NPF guidelines and 2009 AAD guidelines do not recommend systemic corticosteroids as appropriate therapy for psoriasis 1.
Appropriate Alternatives Include:
- First-line systemic agents: Methotrexate, biologics (TNF-α inhibitors, IL-17 inhibitors, IL-23 inhibitors), apremilast, or JAK inhibitors 1, 8, 9
- Phototherapy: For patients requiring non-systemic options 1
- Topical therapies: Corticosteroids, vitamin D analogues for limited disease 1
The One Caveat:
If a patient with psoriasis requires systemic corticosteroids for a separate medical indication (e.g., severe asthma exacerbation, autoimmune disease), the risk-benefit calculation changes 3. In such cases, use the shortest duration and lowest effective dose, with close dermatologic monitoring during tapering 3. Consider bridging to appropriate psoriasis-specific systemic therapy before or during corticosteroid withdrawal 1.
Common Pitfall to Avoid
The most dangerous scenario is prescribing systemic corticosteroids for a psoriasis flare to achieve rapid improvement, then tapering—this creates the exact conditions for severe rebound 2, 3. The temporary benefit is not worth the risk of precipitating pustular or erythrodermic transformation, which may be more difficult to control than the original disease 3.